Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study. In ...

Common stock to continue to trade on NYSE American during the appeal process CRANBURY, N.J., April 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company") (NYSE American: PTN), a ...

CRANBURY, N.J. - Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company with a market capitalization of $4.29 million, has initiated an appeal against the NYSE American’s ...

Roma's Lorenzo Pellegrini (L) and Inter's Henrikh Mkhitaryan (R) in action during the Italian Serie A match AS Roma vs FC Inter at Olimpico stadium in Rome, Italy, 20 October 2024. EPA-EFE/ANGELO ...

Additional trial details are available at clinicaltrials.gov under identifier NCT06565611. Palatin continues to advance its next-generation MC4R agonists, including long-acting peptides and oral ...

Several candidates have been linked with the Roma job in 2025-26 as Claudio Ranieri is expected to step back at the end of the season. The experienced Italian tactician returned to the Stadio ...

CRANBURY, N.J. - Palatin Technologies, Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $18.2 million, has announced encouraging results from its Phase 2 ...

Company working aggressively to regain compliance Common stock to continue to trade on NYSE American during the appeal process CRANBURY, N.J., April 14, 2025 /PRNewswire/ -- Palatin Technologies ...

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177 ...

Company working aggressively to regain compliance Common stock to continue to trade on NYSE American during the appeal process CRANBURY, N.J., April 14, 2025 /PRNewswire/ -- Palatin Technologies ...